zurück

Siponimod

Subject:

  • Active Substance: Siponimod
  • Name: N.N.
  • Therapeutic area: Secondary Progressive Multiple Sclerosis (SPMS)
  • Pharmaceutical company: Novartis Pharma GmbH

 

Time table:

  • Publication of project plan: 20.11.2019
  • Publication of final assessment expected: 13.02.2020

 

Assessment information:

  • Title: Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS)
  • Author/Co-Author: INFARMED (Portugal), NCPE (Ireland)
  • Dedicated Reviewers: AIFA (Italy), ZIN (Netherlands), SESCS/FUNCANIS (Spain), RER (Italy)

› G-BA assessment available (D-513)